西班牙马德里地区HIV感染者多重用药与药物相互作用的人群研究
HIV感染者多重用药比例(32.94%)高于非感染者(22.16%,P<.001),含ARV的禁忌组合患病率为3.18%。含皮质类固醇、喹硫平或抗血栓药物的合并用药与最高风险的红旗DDI相关,使用拉替拉韦或多替拉韦方案与红旗DDI风险降低相关(aOR 0.72,95%CI .60-.88,P=.001)。
要点
- HIV感染者多重用药比例显著高于非感染者,除≥75岁年龄组外各年龄层均一致。
- 含ARV的禁忌组合患病率为3.18%,提示医院与社区处方可能存在脱节。
- 含皮质类固醇、喹硫平或抗血栓药物的合并用药红旗DDI风险最高。
核心结论
- HIV感染者多重用药更常见(32.94% vs 22.16%,P<.001),除≥75岁外各年龄组均一致,女性更常见。
- 含ARV的禁忌组合患病率为3.18%,提示医院与社区处方可能存在脱节。
- 含皮质类固醇、喹硫平或抗血栓药物的合并用药红旗DDI风险最高。
- 使用拉替拉韦或多替拉韦方案与红旗DDI风险降低相关(aOR 0.72,95%CI .60-.88,P=.001)。
研究设计与样本
- 基于人群的研究,链接马德里药物配发登记与利物浦HIV DDI数据库(2017年1月至6月)。
- 多重用药定义为使用≥5种非HIV药物,DDI按交通灯分级评估严重程度。
主要发现
- HIV感染者多重用药比例为32.94%,非感染者为22.16%(P<.001)。
- 除≥75岁年龄组外,各年龄层HIV感染者多重用药均高于非感染者。
- 女性和男性中,HIV感染者多重用药均更常见。
- 含ARV的禁忌组合患病率为3.18%。
- 含皮质类固醇、喹硫平或抗血栓药物的合并用药与最高风险红旗DDI相关。
关键数值与推荐
- 多重用药定义:使用≥5种非HIV药物。
- DDI严重程度采用交通灯分级。
- 拉替拉韦或多替拉韦方案与红旗DDI的aOR为0.72(95%CI .60-.88,P=.001)。
- ARV方案以整合酶抑制剂为主(51.96%)。
临床怎么用
- 对HIV感染者应常规筛查多重用药和DDI,尤其关注皮质类固醇、喹硫平或抗血栓药物。
- 存在DDI风险的患者可考虑换用无增效剂的整合酶抑制剂方案(如拉替拉韦或多替拉韦)。
- 需加强医院与社区处方衔接,避免禁忌组合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Drug-drug interactions (DDIs) that involve antiretrovirals (ARVs) tend to cause harm if unrecognized, especially in the context of comorbidity and polypharmacy. METHODS: A linkage was established between the drug dispensing registry of Madrid and the Liverpool human immunodeficiency virus (HIV) DDI database (January 2017-June 2017). Polypharmacy was defined as the use of ≥5 non-HIV medications, and DDIs were classified by a traffic-light ranking for severity. RESULTS: A total of 22 945 people living with HIV (PLWH) and 6 613 506 individuals without HIV had received medications. ARV regimens were predominantly based on integrase inhibitors (51.96%). Polypharmacy was higher in PLWH (32.94%) than individuals without HIV (22.16%; P < .001); this difference was consistently observed across all age strata except for individuals ≥75 years. Polypharmacy was more common in women than men in both PLWH and individuals without HIV. The prevalence of contraindicated combinations involving ARVs was 3.18%. Comedications containing corticosteroids, quetiapine, or antithrombotic agents were associated with the highest risk for red-flag DDI, and the use of raltegravir- or dolutegravir-based antiretroviral therapy was associated with an adjusted odds ratio of 0.72 (95% confidence interval, .60-.88; P = .001) for red-flag DDI. CONCLUSIONS: Polypharmacy was more frequent among PLWH across all age groups except those aged ≥75 years and was more common in women. The detection of contraindicated medications in PLWH suggests a likely disconnect between hospital and community prescriptions. Switching to alternative unboosted integrase regimens should be considered for patients with risk of harm from DDIs.
引用
- López-Centeno B, Badenes-Olmedo C, Mataix-Sanjuan Á, et al. Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study. Clin Infect Dis. 2020. PMID: 31428770. doi:10.1093/cid/ciz811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。